A detailed history of Marshall Wace, LLP transactions in Argenx Se stock. As of the latest transaction made, Marshall Wace, LLP holds 67,282 shares of ARGX stock, worth $38 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
67,282
Previous 113,772 40.86%
Holding current value
$38 Million
Previous $48.9 Million 25.42%
% of portfolio
0.05%
Previous 0.07%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $20.2 Million - $25.7 Million
-46,490 Reduced 40.86%
67,282 $36.5 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $1.02 Million - $1.29 Million
-2,863 Reduced 2.45%
113,772 $48.9 Million
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $3.23 Million - $3.73 Million
-9,036 Reduced 7.19%
116,635 $45.9 Million
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $62 Million - $92.5 Million
-182,877 Reduced 59.27%
125,671 $47.8 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $43 Million - $63.9 Million
116,433 Added 60.61%
308,548 $152 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $1.51 Million - $1.77 Million
4,181 Added 2.22%
192,115 $74.9 Million
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $19.1 Million - $23.1 Million
57,274 Added 43.83%
187,934 $70 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $10.1 Million - $11.8 Million
29,428 Added 29.07%
130,660 $49.5 Million
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $34.7 Million - $40.1 Million
101,232 New
101,232 $35.7 Million
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $391,853 - $540,632
-1,540 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$272.01 - $353.03 $2.64 Million - $3.43 Million
-9,705 Reduced 86.31%
1,540 $540,000
Q3 2021

Nov 15, 2021

BUY
$295.0 - $350.58 $3.32 Million - $3.94 Million
11,245 New
11,245 $3.4 Million
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $37,626 - $57,966
-353 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$113.31 - $150.51 $39,998 - $53,130
353 New
353 $40,000
Q2 2019

Aug 14, 2019

SELL
$115.0 - $141.58 $111,895 - $137,757
-973 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$98.85 - $134.59 $96,181 - $130,956
973 New
973 $121,000
Q4 2018

Feb 14, 2019

SELL
$63.81 - $109.82 $477,107 - $821,124
-7,477 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$75.5 - $96.63 $564,513 - $722,502
7,477 New
7,477 $567,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.